THE D MAJOR GROUP for ALLERGAN INC (FORMERLY ACTAVIS INC )
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Promote inter partes reform proposals -- specifically, including the Hatch Waxman Integrity Act (S. 344 and H.R. 990). Also, monitor patent reform proposals such as S. 1416, The Affordable Prescriptions for Patients Act of 2019; and S. 440, The PACED Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Policy Analyst for Senate Republican Policy Comt. |
| BRENDA REESE | Conference Coordinator for House Republican Conference |
Health Issues HCR
Worked on industry concerns related to S. 2543, the Prescription Drug Pricing Reduction Act (PDPRA) of 2019; S.1895, the Lower Health Care Costs Act; and S. 3129 and HR 19, the Lower Costs, More Cures Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Analyst for the Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for the House Republican Conference |
Budget/Appropriations BUD
Monitored vaccine and other R&D funding levels as related to HR 6074, the Coronavirus Preparedness & Response Supplemental Appropriations Act; HR 6201, the Families First Coronavirus Response Act; and S. 3548, the Coronavirus Aid, Relief, and Economic Security Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Policy Analyst for Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for House Republican Conference |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.